Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies

[1]  Vincent Doré,et al.  In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Mengchao Cui,et al.  Past and recent progress of molecular imaging probes for β-amyloid plaques in the brain. , 2013, Current medicinal chemistry.

[3]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[4]  C. Masters,et al.  The challenges of tau imaging , 2012 .

[5]  C. Rowe,et al.  In vivo tau imaging in Alzheimer's disease and other dementias , 2012, Alzheimer's & Dementia.

[6]  D. Dickson,et al.  Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: Dickson/Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders , 2011 .

[7]  Kazuhiko Yanai,et al.  18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. , 2011, Brain : a journal of neurology.

[8]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[9]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[10]  E. Mandelkow,et al.  Tau protein and tau aggregation inhibitors , 2010, Neuropharmacology.

[11]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[12]  J. Trojanowski,et al.  Total and phosphorylated tau protein as biological markers of Alzheimer’s disease , 2010, Experimental Gerontology.

[13]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[14]  Bruce H. Morimoto,et al.  Addressing Alzheimer's disease tangles: from NAP to AL-108. , 2009, Current Alzheimer research.

[15]  R. Staff,et al.  Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy , 2009, The journal of nutrition, health & aging.

[16]  C. Broeckhoven,et al.  Invited Article: The Alzheimer disease–frontotemporal lobar degeneration spectrum , 2008, Neurology.

[17]  C. Rowe,et al.  The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias , 2008, Molecular Neurobiology.

[18]  D. Dickson,et al.  Progranulin gene mutation with an unusual clinical and neuropathologic presentation , 2008, Movement disorders : official journal of the Movement Disorder Society.

[19]  M. Bresjanac,et al.  TAU PROTEIN AND HUMAN TAUOPATHIES: AN OVERWIEV* , 2008 .

[20]  A. Delacourte,et al.  Biochemistry of Tau in Alzheimer’s disease and related neurological disorders , 2008, Expert review of proteomics.

[21]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[22]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[23]  C. Jack,et al.  Voxel-based morphometry in autopsy proven PSP and CBD , 2008, Neurobiology of Aging.

[24]  J. Schneider,et al.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration , 2007, Acta Neuropathologica.

[25]  A. Lees,et al.  Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. , 2007, Brain : a journal of neurology.

[26]  C. Rowe,et al.  Imaging β-amyloid burden in aging and dementia , 2007, Neurology.

[27]  K. Arima.  Ultrastructural characteristics of tau filaments in tauopathies: Immuno‐electron microscopic demonstration of tau filaments in tauopathies , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.

[28]  Colin L Masters,et al.  Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics , 2006, Journal of neurochemistry.

[29]  A. Delacourte.  Tauopathies: recent insights into old diseases. , 2006, Folia neuropathologica.

[30]  H. Arai,et al.  Quinoline and Benzimidazole Derivatives: Candidate Probes for In Vivo Imaging of Tau Pathology in Alzheimer's Disease , 2005, The Journal of Neuroscience.

[31]  E. Tolosa,et al.  Progressive supranuclear palsy and corticobasal degeneration: Lumping versus splitting , 2005, Movement disorders : official journal of the Movement Disorder Society.

[32]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[33]  P. Lantos,et al.  Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.

[34]  G. Small,et al.  Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.

[35]  Karl J. Friston,et al.  A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains , 2001, NeuroImage.

[36]  D. Dickson.  Neuropathology of Pick’s disease , 2001, Neurology.

[37]  J. Wall,et al.  Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments. , 2001, The American journal of pathology.

[38]  M. Woodbury,et al.  Density profiles of Alzheimer disease regional brain pathology for the Huddinge brain bank: pattern recognition emulates and expands upon Braak staging , 2000, Experimental Gerontology.

[39]  A. Delacourte,et al.  Tau pathology: a marker of neurodegenerative disorders , 2000, Current opinion in neurology.

[40]  A. Delacourte,et al.  Comparative Biochemistry of Tau in Progressive Supranuclear Palsy, Corticobasal Degeneration, FTDP‐17 and Pick's Disease , 1999, Brain pathology.

[41]  Fran Maher,et al.  Non-Aβ Component of Alzheimer's Disease Amyloid (NAC) Revisited: NAC and α-Synuclein Are Not Associated with Aβ Amyloid , 1999 .

[42]  D. Dickson.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration , 1999, Journal of Neurology.

[43]  T. Miyata,et al.  β2-Microglobulin and Renal Bone Disease , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[44]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[45]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[46]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.

[47]  H. Braak,et al.  Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder , 1994, Neurobiology of Aging.

[48]  P. Mcgeer,et al.  Appearance of paired nucleated, Tau-positive glia in patients with progressive supranuclear palsy brain tissue , 1992, Neuroscience Letters.

[49]  R. Crowther.  Straight and paired helical filaments in Alzheimer disease have a common structural unit. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Kazuhiko Yanai,et al.  Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  D. Dickson.  Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2nd Edition , 2011 .

[52]  R. Coleman,et al.  Use of Florbetapir-PET for Imaging-Amyloid Pathology , 2011 .

[53]  T. Golde.  Alzheimer's Research & Therapy , 2009 .

[54]  T. Uchihara,et al.  Neuropathology of Pick body disease. , 2008, Handbook of clinical neurology.

[55]  Rita H. Miller,et al.  CHAPTER 40 – Introduction , 2008 .

[56]  Maria Luisa Gorno-Tempini,et al.  Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. , 2006, Archives of neurology.

[57]  C. Masters,et al.  Subcellular localization of the Alzheimer's disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.